EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Activation of the 5-HT1A Receptor by Eltoprazine Restores Mitochondrial and Motor Deficits in a Drosophila Model of Fragile X Syndrome

Anna Vannelli, Vittoria Mariano iD, Claudia Bagni, Alexandros K Kanellopoulos iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25168787 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Anna Vannelli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Fundamental Neurosciences, University of Lausanne, 1005 Lausanne, Switzerland. Hauptthemen laut MEDLINE: Fragile X Syndrome, Receptor, Serotonin, 5-HT1A, Mitochondria, Disease Models, Animal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KUL Opening the Future (OTF), Etat de Vaud, Novartis Foundation for medical–biological research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurons rely on mitochondrial energy metabolism for essential functions like neurogenesis, neurotransmission, and synaptic plasticity. Mitochondrial dysfunctions are associated with neurodevelopmental disorders including Fragile X syndrome (FXS), the most common cause of inherited intellectual disability, which also presents with motor skill deficits. However, the precise role of mitochondria in the pathophysiology of FXS remains largely unknown. Notably, previous studies have linked the serotonergic system and mitochondrial activity to FXS. Our study investigates the potential therapeutic role of serotonin receptor 1A (5-HT1A) in FXS. Using the Drosophila model of FXS, we demonstrated that treatment with eltoprazine, a 5-HT1A agonist, can ameliorate synaptic transmission, correct mitochondrial deficits, and ultimately improve motor behavior. While these findings suggest that the 5-HT1A-mitochondrial axis may be a promising therapeutic target, further investigation is needed in the context of FXS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fragile X SyndromeReceptor, Serotonin, 5-HT1AMitochondriaDisease Models, AnimalAnimalsDrosophilaPiperazinesSynaptic TransmissionSerotonin 5-HT1 Receptor AgonistsDrosophila melanogasterMotor Activity

Stichwörter der Autor:innen

FXS therapyeltoprazineintellectual disabilityneuromuscular junctionserotoninsynaptic transmission

Substanzen

Receptor, Serotonin, 5-HT1APiperazinesSerotonin 5-HT1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Fundamental Neurosciences, University of Lausanne, 1005 Lausanne, Switzerland.
  • Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.

ORCID-Profile: Vittoria Mariano, Alexandros K Kanellopoulos

Förderung

  • KUL Opening the Future (OTF)
  • Etat de Vaud
  • Novartis Foundation for medical–biological research
  • PRIN-MUR
  • Autism Speaks Meixner Postdoctoral Fellowship
  • Fondation Pierre Mercier

Zitieren

APA

Vannelli, A., Mariano, V., Bagni, C., & Kanellopoulos, A. K. (2024). Activation of the 5-HT1A Receptor by Eltoprazine Restores Mitochondrial and Motor Deficits in a Drosophila Model of Fragile X Syndrome. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168787

Vancouver

Vannelli A, Mariano V, Bagni C, Kanellopoulos AK. Activation of the 5-HT1A Receptor by Eltoprazine Restores Mitochondrial and Motor Deficits in a Drosophila Model of Fragile X Syndrome. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25168787

BibTeX
@article{Vannelli2024,
  author = {Vannelli, Anna and Mariano, Vittoria and Bagni, Claudia and Kanellopoulos, Alexandros K},
  title = {Activation of the 5-HT1A Receptor by Eltoprazine Restores Mitochondrial and Motor Deficits in a Drosophila Model of Fragile X Syndrome},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25168787}
}
Kostenlos starten →